{"id":"il-2-pre-treated-cd19-cells","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Immune activation-related toxicity"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a cell therapy approach where CD19-expressing cells are pre-treated with interleukin-2 (IL-2) to enhance their immunogenicity and anti-tumor activity. The IL-2 pre-treatment activates and expands the cells, potentially improving their ability to target and kill CD19+ B-cell malignancies. This represents an adoptive cell therapy strategy combining cytokine priming with cellular immunotherapy.","oneSentence":"IL-2 pre-treated CD19-targeted cells enhance immune recognition and elimination of CD19-expressing B-cell malignancies through cytokine-primed cellular immunity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:48:12.331Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"B-cell malignancies expressing CD19"}]},"trialDetails":[{"nctId":"NCT01106950","phase":"PHASE2","title":"Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2010-07","conditions":"Leukemia, Myelogenous, Acute","enrollment":15},{"nctId":"NCT02118285","phase":"PHASE1","title":"Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2014-07-28","conditions":"Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma","enrollment":2},{"nctId":"NCT03030976","phase":"PHASE1","title":"A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)","status":"UNKNOWN","sponsor":"Shanghai GeneChem Co., Ltd.","startDate":"2017-03","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":5},{"nctId":"NCT02992834","phase":"PHASE4","title":"Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma","status":"UNKNOWN","sponsor":"jiangjingting","startDate":"2016-12","conditions":"Lymphoma, B Cell","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"IL-2 pre-treated CD19 cells","genericName":"IL-2 pre-treated CD19 cells","companyName":"jiangjingting","companyId":"jiangjingting","modality":"Biologic","firstApprovalDate":"","aiSummary":"IL-2 pre-treated CD19-targeted cells enhance immune recognition and elimination of CD19-expressing B-cell malignancies through cytokine-primed cellular immunity. Used for B-cell malignancies expressing CD19.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}